TLDR: Swiss pharmaceutical employers who hire digital, data and brand-technology talent compete against the technology labour market, whose senior base pay exceeds the official pharmaceutical median even after bonus is counted.
The official pharma median is CHF 10,159 a month, and that figure already contains bonus and the 13th salary
The most solid number available sits in the Swiss Earnings Structure Survey (ESS) run by the Federal Statistical Office (FSO). Its 2024 results, published on 25 November 2025 and drawn from about 34,000 companies and 2.9 million employees, put the median gross monthly wage in the pharmaceutical industry at 10,159 Swiss francs (CHF), against CHF 9,139 in research and development (R&D), CHF 10,723 in banking and a national median of CHF 7,024.
The FSO converts every salary into a standardised gross monthly wage for 4⅓ weeks of 40 hours, and its methodological annex states that the figure includes one twelfth of the 13th monthly salary and one twelfth of annual special payments or bonuses. Multiplying the monthly figure by twelve therefore gives an annual total cash figure, bonus included. On that basis the median pharmaceutical employee in Switzerland earned about CHF 121,900 a year in 2024, the R&D median about CHF 109,700 and the national median about CHF 84,300.
The pharmaceutical median covers everyone on the payroll of the branch: production operators, laboratory technicians, quality staff, sales, marketing and leadership. It describes the branch, and a single role can sit far above or below it. A recruiter range that quotes “base salary” and an FSO figure that includes bonus describe different things, so a candidate comparing the two can misjudge an offer by the size of the bonus. Edward Galle reads every benchmark with this question first: does the number include variable pay, and is it monthly or annual?
Responsibility level separates a CHF 104,000 package from a CHF 173,000 one more than job title does
The ESS reports pay by education and level of responsibility, and this grid is the closest dated, official proxy for the career ladder inside a life-sciences company. University graduates earned a median of CHF 14,409 a month in posts with a high level of responsibility and CHF 8,645 in posts carrying zero management responsibility. Annualised, that is roughly CHF 172,900 against CHF 103,700, a gap of about two thirds for the same degree. The top tenth of all Swiss employees earned more than CHF 12,526 a month, or about CHF 150,300 a year.
| Federal Statistical Office benchmark, 2024 | Per month (CHF) | Per year, x12 (CHF) |
|---|---|---|
| All employees, national median | 7,024 | 84,288 |
| Research and development, median | 9,139 | 109,668 |
| Pharmaceutical industry, median | 10,159 | 121,908 |
| Banking, median | 10,723 | 128,676 |
| Graduate, individual contributor | 8,645 | 103,740 |
| Graduate, high responsibility | 14,409 | 172,908 |
| Top 10% of all employees, threshold | 12,526 | 150,312 |
In the FSO annex, women in high-responsibility posts earned a median CHF 10,077 a month against CHF 11,715 for men, a 14.0% gap at that level, while the overall median gap narrowed to 8.4% in 2024 from 9.5% in 2022. Region adds its own spread: the same annex puts the median at CHF 7,502 in the Zurich region and CHF 5,708 in Ticino, and the top-decile threshold at CHF 13,970 in Zurich against CHF 12,636 in the Lake Geneva region. A Basel, Zug or Vaud offer has to be read against its own regional and cantonal arithmetic, which the companion piece on how a Swiss offer is built and what it is worth net walks through component by component.
A specialist role with zero direct reports, such as a regulatory, medical information or marketing operations specialist, starts from the graduate individual-contributor line. A head of function with budget and people sits near the high-responsibility line. A leadership title with zero budget and zero reports usually prices like the first line, whatever the business card says.
Digital roles inside life sciences are priced against the technology market, where senior base pay sat near CHF 130,000
Edward Galle’s search work covers brand-tech specialists and revenue operations (RevOps) specialists, the roles that sit between pharma and technology, alongside customer relationship management (CRM), marketing-automation and commercial analytics profiles. These people can work for a pharmaceutical company, an agency, a bank or a software firm, so employers compete for them against the information and communication technology (ICT) market, and that market has its own dated benchmark.
The swissICT salary study 2025, published on 2 September 2025 from 39,511 salary entries supplied by 231 organisations, reported a median base annual salary of CHF 130,060 at senior level, the most frequently reported competence level. Base salaries across the study rose by a modest 0.4%, about CHF 530, compared with 2024. Growth concentrated in a few places: the same study records junior software engineers up 6%, Scrum Masters in lower management up 4.4% and professionals under 30 up to 2%.
Set side by side, the two surveys explain a tension many life-sciences hiring managers feel. The swissICT figure is base pay only, while the FSO pharmaceutical median includes bonus and covers every job in the branch. A senior digital specialist’s base in the ICT market already exceeds the all-branch pharmaceutical total-cash median by roughly CHF 8,000. An employer that anchors a brand-tech or marketing-technology offer on the pharma median, or on the salary of the brand manager the hire will support, lands below the market the candidate actually compares against. The profiles described in Edward Galle’s analysis of brand-tech talent in pharma and medical technology commercial teams are exactly the hybrids caught in this gap.
Bonus culture differs more between branches than base pay does
Variable pay diverges even more by branch. Across all employees, 32.6% received a bonus in 2024, averaging CHF 11,967. At upper-management level, the FSO reports average bonuses of CHF 58,747 in information technology (IT) services against CHF 147,796 in banking and CHF 151,819 in financial and insurance services. A digital leader moving between a software company, a bank and a pharmaceutical group is therefore comparing three different bonus cultures, and the base figure alone hides most of that difference.
Edward Galle’s view is that bonus design is the most underused lever in digital hiring for life sciences. A pharmaceutical group usually runs a short-term incentive tied to company and individual objectives, sometimes with a long-term plan for senior grades. A candidate from a software firm may hold equity or a sales-linked variable component; a candidate from a bank may hold a deferred bonus that vests over several years. Each of these has a cash value on the day of resignation, and a candidate who walks away from a deferred amount expects it to be bought out or offset. Listing every variable component, with its target, its cap and its vesting date, turns an emotional negotiation into an arithmetic one.
The same discipline applies to the employer side. A brand-tech or RevOps role that drives measurable commercial outcomes, such as campaign throughput, CRM data quality or pipeline accuracy, can carry objectives that a candidate from the technology market recognises. A bonus defined only by company results reads to such a candidate as a lottery ticket, and the base figure then has to carry the whole offer.
Pay growth for 2026 is modest, so scarcity carries the negotiation
The FSO wage index shows nominal wages up 1.8% in 2025 and real wages up 1.6%, with the branch grouping that includes chemical and pharmaceutical manufacturing the strongest in manufacturing at plus 3.1%. Looking ahead, the UBS salary survey of 388 companies, published on 5 November 2025, found firms expecting a nominal wage increase of 1.0% for 2026, roughly 0.5% in real terms. Chemicals and pharma expected 1.0% after an effective 1.4% in 2025, banks and insurers 1.0% after 1.5%, and IT and telecom services the highest expectation at 1.7% after 2.0%.
| Indicator | Value | Source, date |
|---|---|---|
| Nominal wages, Switzerland, 2025 | +1.8% | Federal Statistical Office, 21 Apr 2026 |
| Chemical and pharma manufacturing group, 2025 | +3.1% | Federal Statistical Office, 21 Apr 2026 |
| Chemicals and pharma, expected 2026 | +1.0% | UBS, 5 Nov 2025 |
| Information technology and telecom services, expected 2026 | +1.7% | UBS, 5 Nov 2025 |
| Information and communication technology base salaries, 2025 | +0.4% | swissICT, 2 Sep 2025 |
The FSO index tracks wages actually paid across the economy, while UBS asks companies what increase they plan, so the two figures describe the same climate from two angles: the annual round adds about one per cent, and the meaningful jumps come from changing role, scope or employer. In a 1% year, the argument that moves a Swiss offer is evidence of scarcity, a point developed in Edward Galle’s guide to negotiating a Swiss job offer.
A five-point sourcing test separates salary benchmarks from anecdotes
A search for life-sciences salaries in Switzerland returns dozens of neat tables: a regulatory affairs manager at one range, a medical science liaison at another, a head of quality at a third. Edward Galle applied a simple test to each of them before writing this article: a dated publication, a named method and a sample. The pages checked failed it in three recurring ways: some are undated or show only a later update, some state that figures reflect the author’s own placements, and crowd-sourced sites mix base and total pay across regions and years. This article therefore quotes only figures traceable to a dated primary source.
The test is easy to apply to any figure a candidate or a hiring manager meets:
- Date. The publication date and the reference year, which often differ by a year or more. The ESS 2024 appeared in November 2025.
- Definition. Base only, or base plus 13th salary and bonus. The FSO includes both; swissICT reports base.
- Population. One role, one level, or a whole branch. The pharma median covers the entire payroll of the branch.
- Region. Zurich and Ticino differ by almost CHF 1,800 a month at the median.
- Sample. Thousands of companies, a few hundred, or the author’s own desk.
A range that passes all five tests is a benchmark; an offer built on one that fails tends to miss in one direction or the other.
Edward Galle prices a digital offer in life sciences against both markets in four steps
The following sequence is Edward Galle’s own working method for brand-tech, CRM, omnichannel and RevOps mandates with pharmaceutical, medical technology and biotech employers in Switzerland. It uses only the dated public benchmarks above, so any hiring team can repeat it.
Step one: place the role on the responsibility grid. Decide honestly whether the role manages people and budget, coordinates a virtual team, or delivers as an individual expert. The FSO grid then gives the total-cash anchor for the pharmaceutical side of the comparison.
Step two: find the technology-market twin. Every digital role in a commercial team has a twin in the technology market: a marketing-automation lead resembles a platform owner, a CRM data steward resembles a data engineer with business ownership, a RevOps specialist resembles a sales-operations analyst in a software company. The swissICT study gives the base anchor for that twin, at the matching competence level.
Step three: convert both anchors to the same definition. Add the expected bonus to the technology base, or strip the bonus share out of the FSO total, so the two numbers describe the same thing. Then adjust for region, using the FSO regional medians, and for the 13th salary, which most Swiss life-sciences employers pay.
Step four: decide where the offer sits between the two anchors, and say why. A role that needs regulated-industry knowledge, such as medical, legal and regulatory review of promotional material or pharmacovigilance-compliant social listening, earns a premium over a pure technology profile because the pool is smaller. A role that a strong generalist from any sector can fill within weeks prices nearer the technology base. Writing this reasoning into the approval memo shortens the internal sign-off, because finance and human resources (HR) can see which benchmark drives the number.
Two mistakes recur in Edward Galle’s searches. The first is benchmarking a digital hire against the internal grade of the brand team it supports, which fixes the offer on the pharmaceutical line from the start. The second is quoting a base figure to a candidate whose current package carries a large deferred bonus, which ends the conversation before the role is even described.
Candidates and employers who price digital roles against both markets close Swiss searches faster
Candidats moving into or within Swiss life sciences can place themselves on the FSO responsibility grid first, then adjust for region and for the bonus culture of the target employer. A digital or data profile should carry the swissICT benchmark into the conversation, because that is the market the skills trade in. Evidence of a scarce combination, such as CRM platform administration plus experience with medical, legal and regulatory review, moves an offer further than a generic request for more. A one-page summary of current base, bonus target, deferred amounts with vesting dates, and notice period gives the hiring team everything it needs to build a credible offer in one round.
Employeurs hiring brand-tech, CRM, omnichannel or analytics talent can benchmark against both markets before the first interview. Where the internal pay band was built for pharma marketing roles, the gap to the ICT market is usually visible on day one, and closing it early through base, bonus design or role scope keeps the search moving. Edward Galle supports both sides of that conversation: candidates can submit a curriculum vitae (CV) for confidential matching, and current mandates are listed on the jobs page.
This article has been reviewed by Haider Alleg, Managing Partner at Kainjoo SA.
References
- Federal Statistical Office (FSO). 2024 lag der Medianlohn bei 7024 Franken brutto (Swiss Earnings Structure Survey 2024, initial findings). 25 November 2025. https://www.admin.ch/de/newnsb/CzozNgBTCJOrNyvwsItyp
- Federal Statistical Office (FSO). Schweizerische Lohnstrukturerhebung 2024: erste Ergebnisse, press release with methodological annex. 25 November 2025. https://dam-api.bfs.admin.ch/hub/api/dam/assets/36195847/master
- swissICT. Saläre der ICT 2025: Moderate Lohnentwicklung und vertiefte Einblicke in Anstellungsbedingungen. 2 September 2025. https://www.swissict.ch/salaere-der-ict-2025/
- Federal Statistical Office (FSO). Die Reallöhne sind im Jahr 2025 um 1,6% gestiegen. 21 April 2026. https://www.admin.ch/de/newnsb/Eh5oOnuiTBX189E3wK0yM
- UBS. UBS Outlook Schweiz, salary survey 2026. 5 November 2025. https://www.ubs.com/global/de/media/display-page-ndp/de-20251105-outlook.html
